Sangamo Therapeutics Announces Dosing of First Patient in Phase I/II Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Sangamo Therapeutics, Inc. announced dosing of the first patient in the Phase I/II STEADFAST clinical study evaluating TX200, a wholly-owned autologous CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.